36093-85-3

Basic information

• Product Name: 4-(N-[2,4-DIAMINO-6-PTERIDINYLMETHYL]-AMINO)BENZOIC ACID SODIUM SALT
• Synonyms: 4-AMINO-4-DEOXYPTEROIC ACID SODIUM SALT;4-[N-(2,4-DIAMINO-6-PTERIDINYLMETHYL)AMINO]BENZOIC ACID SODIUM;4-(N-[2,4-DIAMINO-6-PTERIDINYLMETHYL]-AMINO)BENZOIC ACID SODIUM SALT;4-(N-((2,4-diamino-6-pteridinyl)methyl)amino)benzoic acid;4-[[(2,4-Diamino-6-pteridinyl)methyl]amino]benzoic acid;Aminopteroic acid;Benzoic acid, 4-[[(2,4-diaMino-6-pteridinyl)Methyl]aMino]-;4-AMinodeoxopteroic Acid
• CAS NO: 36093-85-3
• Molecular Formula: C₁₄H₁₃N₇O₂
• Molecular Weight: 333.28
• Product Categories: Amino Acids & Derivatives, Aromatics, Heterocycles, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 36093-85-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 681.8°C at 760 mmHg
• Flash Point: 366.1°C
• Appearance: /
• Density: 1.607g/cm³
• Vapor Pressure: 1.6E-19mmHg at 25°C
• Refractive Index: 1.842
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly, Heated), Methaol (Slightly)
• CAS DataBase Reference: 4-(N-[2,4-DIAMINO-6-PTERIDINYLMETHYL]-AMINO)BENZOIC ACID SODIUM SALT(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(N-[2,4-DIAMINO-6-PTERIDINYLMETHYL]-AMINO)BENZOIC ACID SODIUM SALT(36093-85-3)
• EPA Substance Registry System: 4-(N-[2,4-DIAMINO-6-PTERIDINYLMETHYL]-AMINO)BENZOIC ACID SODIUM SALT(36093-85-3)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22
• Safety Statements: 36
• WGK Germany: 3
• Hazardous Substances Data: 36093-85-3(Hazardous Substances Data)

Usage

Uses

4-(N-[2,4-DIAMINO-6-PTERIDINYLMETHYL]-AMINO)BENZOIC ACID SODIUM SALT is an intermediate for the synthesis of Aminopterin (A628850), a folic acid antagonist. They can also be used as precursors for De Novo synthesis of antifolates: A novel class of antimalarials.

InChI:InChI=1/C14H13N7O2/c15-11-10-12(21-14(16)20-11)18-6-9(19-10)5-17-8-3-1-7(2-4-8)13(22)23/h1-4,6,17H,5H2,(H,22,23)(H4,15,16,18,20,21)

Upstream product

• 54-62-6 aminopterin 
• 945-24-4 2,4-diamino-6-(hydroxymethyl)pteridine 
• 89852-78-8 2,4-diamino-5,6,7,8-tetrahydro-6-hydroxymethylpteridine 
• 150-13-0 4-amino-benzoic acid 
• 46046-65-5 pteridin-6-yl-methanol 
• 100929-45-1 sodium salt of 4-amino-4-deoxypteroic acid 
• 77773-81-0 1-<(2,4-Diamino-5-nitropyrimidin-6-yl)amino>-2,2-dimethoxy-3-<(p-carboxyphenyl)amino>propane 
• 77773-77-4 4-[(3-Azido-2,2-dimethoxy-propyl)-(2,2,2-trifluoro-acetyl)-amino]-benzoic acid ethyl ester 
• 77773-78-5 N-(1-Azido-2,2-dimethoxypropyl)-p-aminobenzoic acid 
• 77773-79-6 N-(1-Amino-2,2-dimethoxypropyl)-p-aminobenzoic acid 
• 52853-40-4 6-bromomethyl-2,4-diaminopteridine hydrobromide 
• 77773-82-1 4-[3-(2,6-Diamino-5-nitro-pyrimidin-4-ylamino)-2-oxo-propylamino]-benzoic acid 

Downstream Products

• 100929-45-1 sodium salt of 4-amino-4-deoxypteroic acid 
• 1219142-62-7 C₃₁H₃₇N₁₁O₆S₂ 
• 54-62-6 aminopterin 
• 89043-76-5 (S)-2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-formyl-amino]-benzoylamino}-4-sulfo-butyric acid methyl ester 
• 89043-76-5 2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-formyl-amino]-benzoylamino}-4-sulfo-butyric acid methyl ester 
• 89043-73-2 N-(4-amino-1-deoxypteroyl)-L-homocysteic acid 
• 96193-19-0 2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-amino]-benzoylamino}-4-sulfo-butyric acid 
• 89043-74-3 N-(4-amino-4-deoxypteroyl)-L-cysteic acid 
• 95484-99-4 α-methyl γ-tert-butyl N-(4-amino-4-deoxy-N¹⁰-formylpteroyl)-L-glutamate 
• 95485-00-0 γ-tert-butyl N-(4-amino-4-deoxy-N¹⁰-formylpteroyl)-L-glutamate 
• 89043-77-6 (R)-2-{4-[(2,4-Diamino-pteridin-6-ylmethyl)-formyl-amino]-benzoylamino}-3-sulfo-propionic acid methyl ester 
• 95484-98-3 γ-tert-butyl N-(4-amino-4-deoxypteroyl)-L-glutamate 
• 95485-01-1 p-nitrophenyl 4-amino-4-deoxy-N¹⁰-formylpteroate 
• 158090-71-2 3,5-Dichloro-4-[(2,4-diamino-pteridin-6-ylmethyl)-formyl-amino]-benzoic acid 

Relevant articles and documents

Methods of treating inflammatory diseases with ammonium salts of ornitihine derivatives

The present invention relates to pharmaceutically active ornithine compounds, particularly to pharmaceutically acceptable ammonium salts of Nδ-acyl derivatives of Nα(4-amino-4-deoxypteroyl)-L-ornithine compounds; and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such ammonium salts. The ammonium salts provided by the invention exhibit superior chemical stability than corresponding acidic Nδ-acyl derivatives of Nδ-acyl derivatives of Nα(4-amino-4-deoxypteroyl)-L-ornithine compounds.

Methotrexate analogues. 25. Chemical and biological studies on the γ-tert-Butyl esters of methotrexate and aminopterin

γ-tert-Butylaminopterin (γ-tBAMT), the first example of an aminopterin (AMT) γ-monoester, was synthesized, and new routes to the known N10-methyl analogue γ-tert-butyl methotrexate (γ-tBMTX were developed. The inhibitory effects of γ-tBAMT on the activity of purified dihydrofolate reductase (DHFR) from L1210 murine leukemia cells, the growth of L1210 cells and CEM human leukemic lymphoblasts in suspension culture, and the growth of several lines of human squamous cell carcinoma of the head and neck in monolayer culture were compared with the effects of γ-tBMTX and the parent acids AMT and methotrexate (MTX). Patterns of cross-resistance to γ-tBAMT, γ-tBMTX, and AMT among several MTX-resistant cell lines were examined. In vivo antitumor activities of γ-tBAMT and γ-tBMTX were compared in mice with L1210 leukemia. While the activity of γ-tBAMT was very close to that of γ-tBMTX in the DHFR inhibition assay, the AMT ester was more potent than the MTX ester against cells in culture and against L1210 leukemia in vivo. Only partial cross-resistance was shown against γ-tBMTX and γ-tBAMT in cultured cells that were resistant to MTX by virtue of a transport defect or a combination of defective transport and elevated DHFR activity.

Folate analogues. XVII. Synthesis of pteroic acid and 4-amino-4-deoxypteroic acid

-